- Xebra Brands (CSE:XBRA) announced that its European subsidiary is pursuing a number of opportunities enabled by a regulatory breakthrough in the Netherlands
- This comes after it was issued a Dutch cannabis cultivation license for scientific research in June 2024, which granted Xebra the right to legally cultivate and process cannabis for scientific purposes
- Since receiving the license, Xebra has been assessing a number of strategic opportunities to monetize this license and support a broad set of business applications
- Xebra Brands stock (CSE:XBRA) last traded at $0.05
Xebra Brands (CSE:XBRA) announced that its European subsidiary is pursuing a number of opportunities enabled by a regulatory breakthrough in the Netherlands.
Going Dutch
This comes after it was issued a Dutch cannabis cultivation license for scientific research in June, 2024. The license, issued by the Minister of Health, Welfare and Sport, on behalf of the Minister, Head of the Bureau for Medicinal Cannabis, granted Xebra an opium exemption (for cannabis purposes) number 109230 CO/w, the right to legally cultivate and process cannabis for scientific purposes in its R&D facility built in the village of Wilp in the Dutch province of Gelderland. The Netherlands is recognized as a pioneer in cannabis regulation and research within Europe.
“This license marked a major milestone for our European operations,” Rodrigo Gallardo, Xebra Brands’ interim CEO said in a media release. “Now, upon examination of the licensing guidelines and with the regulatory foundation in place, we are identifying the highest-value commercial and research opportunities that align with our long-term vision.”
Since receiving the license, Xebra has been assessing a number of strategic opportunities to monetize this license and support a broad set of business applications.
Key business opportunities under evaluation
- Cannabis genetics R&D: Establishing breeding programs to develop proprietary cultivars for medical, wellness, and commercial applications, with a focus on intellectual property and export potential.
- Partnerships: Collaborations with European entities in wellness, research, agriculture, and manufacturing to support market expansion and innovation.
- Products: Designing and developing differentiated cannabis-based products tailored to European regulatory standards and consumer preferences.
- Exports: Utilizing the Netherlands as a production and export hub to serve other EU countries with legal medical cannabis frameworks.
- Manufacturing: Providing compliant cultivation and processing capabilities for third-party brands looking to enter the European market.
- Collaborations: Supporting evidence-based cannabis applications through research projects and lab partnerships.
- Sales: Anticipating future regulatory shifts that may allow for legal recreational cannabis sales through licensed retail operations.
The Xebra team views the Dutch license as a long-term strategic asset and continues to explore the evolving regulatory and commercial landscape across Europe.
About Xebra Brands
With headquarters out of Vancouver, Xebra Brands Ltd. is focused on the development and sale of cannabis and CBD products in Mexico.
Xebra Brands stock (CSE:XBRA) last traded at $0.05 and though down 50 per cent since this time last year, it is up 100 per cent since the year began.
Join the discussion: Find out what everybody’s saying about this stock on the Xebra Brands Ltd. Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
